Original Investigation  |  CARING FOR THE CRITICALLY ILL PATIENT

Protocolized Sedation vs Usual Care in Pediatric Patients Mechanically Ventilated for Acute Respiratory Failure
A Randomized Clinical Trial

Martha A. Q. Curley, RN, PhD; David Wypij, PhD; R. Scott Watson, MD, MPH; Mary Jo C. Grant, APRN, PhD; Lisa A. Asaro, MS; Ira M. Cheifetz, MD; Brenda L. Dodson, PharmD; Linda S. Franck, RN, PhD; Rainer G. Gedeit, MD; Derek C. Angus, MD, MPH; Michael A. Matthay, MD; for the RESTORE Study Investigators and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network

**IMPORTANCE** Protocolized sedation improves clinical outcomes in critically ill adults, but its effect in children is unknown.

**OBJECTIVE** To determine whether critically ill children managed with a nurse-implemented, goal-directed sedation protocol experience fewer days of mechanical ventilation than patients receiving usual care.

**DESIGN, SETTING, AND PARTICIPANTS** Cluster randomized trial conducted in 31 US pediatric intensive care units (PICUs). A total of 2449 children (mean age, 4.7 years; range, 2 weeks to 17 years) mechanically ventilated for acute respiratory failure were enrolled in 2009-2013 and followed up until 72 hours after opioids were discontinued, 28 days, or hospital discharge.

**INTERVENTION** Intervention PICUs (17 sites; n = 1225 patients) used a protocol that included targeted sedation, arousal assessments, extubation readiness testing, sedation adjustment every 8 hours, and sedation weaning. Control PICUs (14 sites; n = 1224 patients) managed sedation per usual care.

**MAIN OUTCOMES AND MEASURES** The primary outcome was duration of mechanical ventilation. Secondary outcomes included time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, neurological testing, PICU and hospital lengths of stay, in-hospital mortality, sedation-related adverse events, measures of sedative exposure (wakefulness, pain, and agitation), and occurrence of iatrogenic withdrawal.

**RESULTS** Duration of mechanical ventilation was not different between the 2 groups (intervention: median, 6.5 [IQR, 4.1-11.2] days; control: median, 6.5 [IQR, 3.7-12.1] days). Sedation-related adverse events including inadequate pain and sedation management, clinically significant iatrogenic withdrawal, and unplanned endotracheal tube/invasive line removal were not significantly different between the 2 groups. Intervention patients experienced more postextubation stridor (7% vs 4%; P = .03) and fewer stage 2 or worse immobility-related pressure ulcers (<1% vs 2%; P = .001). In exploratory analyses, intervention patients had fewer days of opioid administration (median, 9 [IQR, 5-15] days vs 10 [IQR, 4-21] days; P = .01), were exposed to fewer sedative classes (median, 2 [IQR, 2-3] classes vs 3 [IQR, 2-4] classes; P < .001), and were more often awake and calm while intubated (median, 86% [IQR, 67%-100%] of days vs 75% [IQR, 50%-100%] of days; P = .004) than control patients, respectively; however, intervention patients had more days with any report of a pain score ≥4 (median, 50% [IQR, 27%-67%] of days vs 23% [IQR, 0%-46%] of days; P < .001) and any report of agitation (median, 60% [IQR, 33%-80%] vs 40% [IQR, 13%-67%]; P = .003), respectively.

**CONCLUSIONS AND RELEVANCE** Among children undergoing mechanical ventilation for acute respiratory failure, the use of a sedation protocol compared with usual care did not reduce the duration of mechanical ventilation. Exploratory analyses of secondary outcomes suggest a complex relationship among wakefulness, pain, and agitation.

**TRIAL REGISTRATION** clinicaltrials.gov Identifier: NCT00814099

Published online January 20, 2015.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) study investigators are listed in Supplement 1.

Corresponding Author: Martha A. Q. Curley, RN, PhD, University of Pennsylvania, Claire M. Fagin Hall, 418 Curie Blvd–425, Philadelphia, PA 19104-4217 (curley@nursing.upenn.edu).
Ensuring the safety and comfort of critically ill infants and children supported by mechanical ventilation is integral to the practice of pediatric care. Although sedation therapy benefits young patients who cannot understand the imperative nature of invasive life-sustaining therapies, sedative use is also associated with untoward adverse effects. Specifically, opioids and benzodiazepines commonly used for pediatric sedation may impair bedside neurological assessment, depress spontaneous ventilation, and prolong mechanical ventilation. Over time, drug tolerance develops, which may precipitate iatrogenic withdrawal syndrome when sedation therapy is no longer necessary.

Numerous studies in adult critical care support a minimal yet effective approach to sedation management. Sedation goals for mechanically ventilated adults have shifted from an unresponsive state to a calm, easily aroused, readily evaluated patient. Studies in adult patients evaluating targeted sedation, daily interruption and/or titration of sedation, pairing of spontaneous awakening with breathing, and no sedation have reported improved clinical outcomes, including decreased length of mechanical ventilation when compared with usual care.

In contrast, few data inform sedation practices in pediatric critical care, and international studies describe significant practice variation. Given unique biobehavioral differences, knowledge generated in adult critical care may not translate to the care of critically ill children. We conducted a multicenter cluster randomized clinical trial to test the effect of a nurse-implemented, goal-directed sedation protocol on clinical outcomes in pediatric patients with acute respiratory failure. Our primary aim was to determine whether critically ill children managed with a nurse-implemented, goal-directed sedation protocol would experience fewer days of mechanical ventilation than patients receiving usual care.

### Methods

#### Study Design

This unblinded, multicenter, cluster randomized clinical trial conducted in the United States tested an intervention that changed how intensive care teams worked together to manage a patient’s level of sedation on a day-to-day basis. To avoid patient-level contamination from this system-level organizational change in sedation practice, the unit of randomization was the pediatric intensive care unit (PICU), the unit of analysis was the patient, and we accounted for site effects (Figure 1).

PICUs were recruited from the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Eligible PICUs did not have a sedation protocol in place; showed evidence of nursing and physician leadership support; agreed to the research design, in which approximately half of the PICUs would be randomized to the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) intervention as a research protocol and half to continued usual care; and could enroll a minimum of 3 patients per month. We obtained approval from each institutional review board as well as written informed consent from the legal guardian of each enrolled patient.

During the baseline phase, all PICUs implemented the same pediatric-specific standard, valid, and reliable pain, sedation, and iatrogenic withdrawal assessment instruments. The pain scale used depended on patient age and verbal/cognitive capacity: the FLACC (Face, Legs, Activity, Cry, Consolability) scale in nonverbal children 0 to 6 years of age; the Individualized Numeric Rating Scale in nonverbal cognitively impaired children aged 6 years or older; and the Wong-Baker Faces Pain Scale in verbal children aged 3 years or older. All pain scales range from 0 to 10, with higher scores indicating more pain. Level of sedation in intubated patients was assessed using the State Behavioral Scale (SBS). The SBS scores range from −3 (unresponsive) to +2 (agitated), with a preferred SBS of −1 (responsive to gentle touch or voice). In patients receiving neuromuscular blockade, pain/agitation was judged to be present when a patient demonstrated at least a 20% increase in heart rate or blood pressure when stimulated. All patients weaning from 5 days or longer of opioid use were monitored for opioid or benzodiazepine withdrawal symptoms using the Withdrawal Assessment Tool-Version 1 (WAT-1). The WAT-1 scale ranges from 0 to 12, with higher scores indicating more withdrawal symptoms.

Prior to randomization, PICUs were given a copy of the protocol that described the intervention only in general terms. PICUs provided baseline data that allowed a comparison of available patient population and major organizational factors (eTables 1 and 2 in Supplement 1). PICUs were grouped by the number of eligible patients as small, medium, or large. The study began with 22 PICUs that were stratified by size and, within each stratum, assigned to the intervention or control group via computer-generated random numbers so that approximately half were assigned to each group. To increase enrollment rates 1 year after study initiation, 9 PICUs were added following the same procedures. Anticipating lower consent rates in the intervention group, in which parents consented for study treatment rather than data collection alone, we randomized more PICUs to the intervention group.

Patients aged 2 weeks to 17 years receiving invasive mechanical ventilation for acute airways and/or parenchymal lung disease were eligible. We excluded patients whose length of mechanical ventilation was unlikely to be altered by sedation management; for example, patients undergoing ventilation only for postoperative care or those expected to be extubated within 24 hours (eTable 3 in Supplement 1). PICUs screened all intubated patients daily. Guardians were approached for consent within 24 hours of the patient meeting study criteria, with the goal of protocol initiation within 48 hours.
Sedation Protocol

The RESTORE protocol includes interprofessional team training and the use of a nurse-implemented, goal-directed comfort algorithm to guide sedation therapy (trial algorithm available in Supplement 2). Core elements included daily team discussion of the patient’s trajectory of illness (acute, titration, or weaning phase); prescribing an SBS target score per phase of illness; modified arousal assessment if responsive only to noxious stimuli (SBS score = −2) or full arousal assessment if unresponsive to stimulation (SBS score = −3) in the titration/weaning phases; daily extubation readiness test (ERT) when spontaneously breathing with an oxygenation index of 6 or lower; adjustment of sedatives based on phase of illness at least every 8 hours; discontinuation of opioids and benzodiazepines when no longer necessary (if exposed <5 days) or weaned per target WAT-1 score (if exposed ≥5 days); and a written sedation weaning plan when transferred out of the PICU.

Patients meeting ERT criteria underwent testing each morning.20 Results of the ERT were discussed during multidisciplinary rounds. If the ERT results showed failure because of excessive sedation, the team weaned sedation and retested the patient. If the ERT results indicated extubation readiness, the team extubated the patient within 6 hours or chose to keep the patient intubated for nonpulmonary reasons. Postextubation pulmonary management was not protocolized.

The protocol delineated how sedatives, typically prescribed in the PICU, were managed. Primary sedative agents included morphine and midazolam.13 Fentanyl was recommended as a primary agent for patients with hypotension or reactive airways disease. Morphine was selected as the primary opioid because compared with fentanyl, it has a longer duration of action and some sedative properties. In addition, tolerance is thought to occur more rapidly with the short-acting opioid fentanyl.13 Secondary sedative agents included dexmedetomidine or propofol to facilitate extubation and clonidine, pentobarbital, or ketamine when unresponsive to primary agents. Clonidine was also recommended to manage iatrogenic withdrawal, with methadone recommended only if WAT-1 scores continued to be above target. Nurses used the algorithm with a standardized order set to manage sedation per phase of illness and prescribed SBS score.

After randomization, coinvestigators from each intervention PICU attended a startup meeting during which they received the algorithm and training materials that included discipline-specific slide packages, digital file of an arousal assessment, pocket reminder cards, and bedside booklets. Site coinvestigators then customized the training materials for their PICU and conducted training that included lectures, informal case discussions, and self-learning packages. All clinicians involved in the management of mechanically ventilated patients (physicians, nursing staff, and clinical pharmacists) were trained and were required to demonstrate understanding of the intervention by completion of a discipline-specific, scenario-based posttest. Respiratory therapists were trained in evaluating patient readiness for extubation and synchronizing the ERT with an evaluation of the patient’s SBS score. Training was also embedded into unit orientation programs to accommodate new and rotating staffs. On average, PICUs reported training a mean of 164 (SD, 99) staff members, primarily nurses (mean, 114 [SD, 71]). This required spending a mean of 1.4 (SD, 0.9) hours per person on initial protocol train-
ing followed by an additional mean of 1.4 (SD, 1.1) hours per person in maintenance training through the course of the study.

Control PICUs did not receive a copy of the algorithm and managed sedation per usual care without a protocol. Sedatives were selected, prescribed, and titrated at the discretion of the medical team. No recommendations were made for extubation readiness testing.

**Outcome Measures and Statistical Analysis**

The primary outcome was duration of mechanical ventilation, beginning on day 0 at the time of endotracheal intubation, initiation of assisted breathing for patients with tracheostomies, or PICU admission for patients intubated at an outside hospital, and continuing until the first time the endotracheal tube was continuously absent for at least 24 hours or, in patients with tracheostomies, the first time pressure support was less than 5 cm H₂O (continuous or bilevel) for at least 24 hours. Patients were assigned 28 days if they remained intubated or were transferred or died prior to day 28 without remaining extubated for more than 24 hours, therefore making the primary outcome equivalent to ventilator-free days.

All secondary outcomes were selected a priori and included time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, neurological testing, PICU and hospital lengths of stay, in-hospital mortality, sedation-related adverse events, sedative exposure, and occurrence of iatrogenic withdrawal (eTable 4 in Supplement 1). Sedative exposure and sedation outcomes included measures of wakefulness, pain, and agitation; specifically, percentage of study days awake and calm (daily modal SBS score = −1 [responsive to gentle touch or voice] or 0 [awake and able to calm]), number of days to first awake/calm state, percentage of study days with modal pain score lower than 4, and percentage of study days with any episode of pain (highest daily pain score >4) or agitation (highest daily SBS score = +1/+2 [restless and difficult to calm/agitated]).

Sedation-related adverse events were also defined a priori and prospectively monitored (eTable 4 in Supplement 1). These included inadequate pain management (pain score >4 [or pain assumed present if receiving neuromuscular blockade] for 2 consecutive hours), inadequate sedation management (SBS score >0 [or agitation assumed present if receiving neuromuscular blockade] for 2 consecutive hours), clinically significant iatrogenic withdrawal in patients weaning from 5 or more days of opioids (rescue therapy to manage an increase in WAT-1 symptoms), extubation failure (reintubation within 24 hours), postextubation stridor, unplanned extubation, unplanned removal of any invasive tube, ventilator-associated pneumonia, catheter-associated bloodstream infection, immobility-related stage 2 or worse pressure ulcers, and new tracheostomy.

The primary analysis compared the duration of mechanical ventilation in intervention vs control patients using Kaplan-Meier curves and proportional hazards regression adjusting for age group (2 weeks to 1.99 years, 2.00 to 5.99 years, or 6.00 to 17.99 years), Pediatric Risk of Mortality (PRISM) III-12 score, and Pediatric Overall Performance Category (POPC) score. Exploratory analyses of secondary outcomes used logistic, multinomial logistic, cumulative logit, linear, and Poisson regression accounting for PICU as a cluster variable using generalized estimating equations for binary, nominal, ordinal, continuous, and rate variables, respectively. Statistical analyses were performed with SAS software, version 9.4 (SAS Institute Inc) using 2-sided α = .05 level tests.

A priori, the study team determined that a 20% reduction in the duration of mechanical ventilation, or a hazard ratio (HR) of 1.25, was clinically important for patients managed with the sedation protocol and plausible based on our pilot study. Assuming independent observations, proportional hazards between groups, and that up to 15% of patients would not be successfully extubated by day 28, 1050 patients were required for a 2-sided α = .05 level log-rank test to achieve 90% power to detect a 20% reduction assuming 3 interim analyses to assess efficacy or futility using an O’Brien-Fleming stopping rule (East, version 5.3, Cytel Statistical Software). To account for the intraclass correlation coefficient in our cluster randomized design and using an intraclass correlation coefficient of 0.01 from previous experience and conservatively assuming 22 sites, 1990 patients were required. We chose 2448 patients as our target sample size to guarantee 90% power to detect a 20% reduction in length of ventilation controlling for patients not successfully extubated by day 28, 3 formal interim analyses, and modest within-site correlations. This allowed for moderate site-to-site variability in cluster sizes and adjustment for age group, PRISM III-12 score, and POPC score greater than 1.

**Study Oversight**

Case report forms were designed to capture and allow adherence monitoring of core elements of the study protocol. In the intervention group, site coinvestigators rounded daily on each patient, separately from clinical rounds, to monitor patient safety, adverse events, and protocol adherence. Monthly adherence reports provided clinical teams with feedback on their sedation management performance. In the control group, auditors observed for the use of any sedation protocol during site visits. All sites participated in yearly individual site calls to review their study performance.

An independent data and safety monitoring board appointed by the National Heart, Lung, and Blood Institute oversaw all aspects of the trial, including performance, data quality, safety, and ethics. The board monitored adverse events, protocol adherence, and potential early stopping for efficacy or futility.

**Results**

**Characteristics of Study Units and Participants**

Thirty-one PICUs participated (Figure 1 and eTables 1 and 2 in Supplement 1). From June 2009 through December 2013, 2449 patients were enrolled, 1225 from 17 intervention sites and 1224 from 14 control sites. The percentage of intubated patients who were eligible was not statistically significantly different be-
Table 1. Baseline Characteristics of Study Patients According to Group

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Sedation Protocol (n = 1225)</th>
<th>Usual Care (n = 1224)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at PICU admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR), y</td>
<td>1.4 (0.3-7.0)</td>
<td>2.6 (0.6-9.2)</td>
<td>.002</td>
</tr>
<tr>
<td>No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 wk to 1.99 y</td>
<td>715 (58)</td>
<td>550 (45)</td>
<td></td>
</tr>
<tr>
<td>2.00 to 5.99 y</td>
<td>176 (14)</td>
<td>243 (20)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6.00 to 17.99 y</td>
<td>334 (27)</td>
<td>431 (35)</td>
<td></td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>558 (46)</td>
<td>543 (44)</td>
<td>.53</td>
</tr>
<tr>
<td>Non-Hispanic white, No./total (%)</td>
<td>631/1215 (52)</td>
<td>602/1210 (50)</td>
<td>.81</td>
</tr>
<tr>
<td>Baseline POPC score</td>
<td>1, No. (%)¹&lt;sup&gt;b&lt;/sup&gt;</td>
<td>942 (77)</td>
<td>.41</td>
</tr>
<tr>
<td>Baseline POPC score = 1, No. (%)²&lt;sup&gt;b&lt;/sup&gt;</td>
<td>885 (72)</td>
<td>862 (70)</td>
<td>.51</td>
</tr>
<tr>
<td>Able to verbally communicate pain at baseline, No./total (%)³&lt;sup&gt;b&lt;/sup&gt;</td>
<td>398/616 (65)</td>
<td>565/768 (74)</td>
<td>.21</td>
</tr>
<tr>
<td>PRISM III-12 score, median (IQR)</td>
<td>6 (3-11)</td>
<td>8 (5-13.5)</td>
<td>.005</td>
</tr>
<tr>
<td>Risk of mortality based on PRISM III-12 score, median (IQR), %</td>
<td>2.4 (1.0-9.5)</td>
<td>4.8 (1.7-15.0)</td>
<td>.01</td>
</tr>
<tr>
<td>Aged 2 wk to 1.99 y</td>
<td>1.7 (0.7-4.9)</td>
<td>3.8 (1.3-9.5)</td>
<td>.003</td>
</tr>
<tr>
<td>Aged 2.00 to 5.99 y</td>
<td>3.3 (1.2-17.2)</td>
<td>4.8 (1.7-17.0)</td>
<td>.56</td>
</tr>
<tr>
<td>Aged 6.00 to 17.99 y</td>
<td>7.7 (1.8-19.6)</td>
<td>7.7 (2.2-26.2)</td>
<td>.54</td>
</tr>
<tr>
<td>Primary diagnosis, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>394 (32)</td>
<td>433 (35)</td>
<td></td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td>428 (35)</td>
<td>228 (19)</td>
<td></td>
</tr>
<tr>
<td>Acute respiratory failure related to sepsis</td>
<td>145 (12)</td>
<td>212 (17)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Asthma or reactive airway disease</td>
<td>87 (7)</td>
<td>120 (10)</td>
<td></td>
</tr>
<tr>
<td>Aspiration pneumonia</td>
<td>70 (6)</td>
<td>79 (6)</td>
<td></td>
</tr>
<tr>
<td>Other&lt;sup&gt;d&lt;/sup&gt;</td>
<td>101 (8)</td>
<td>152 (12)</td>
<td></td>
</tr>
<tr>
<td>PARDS&lt;sup&gt;3,3&lt;/sup&gt; based on day 1 OI or OSI, No. (%)&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At risk (OI &lt;4.0 or OSI &lt;5.0)</td>
<td>472 (39)</td>
<td>460 (38)</td>
<td></td>
</tr>
<tr>
<td>Mild (OI=4.0-7.9 or OSI=5.0-7.4)</td>
<td>308 (25)</td>
<td>351 (29)</td>
<td>.83</td>
</tr>
<tr>
<td>Moderate (OI=8.0-16.0 or OSI=7.5-12.3)</td>
<td>279 (23)</td>
<td>254 (21)</td>
<td></td>
</tr>
<tr>
<td>Severe (OI=16.0 or OSI=12.3)</td>
<td>166 (14)</td>
<td>159 (13)</td>
<td></td>
</tr>
<tr>
<td>Neuromuscular blockade for the entire duration of days 0 to 2, No. (%)</td>
<td>82 (7)</td>
<td>92 (8)</td>
<td>.64</td>
</tr>
<tr>
<td>Any medical history, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prematurity (&lt;36 wk postmenstrual age)</td>
<td>194 (16)</td>
<td>175 (14)</td>
<td>.37</td>
</tr>
<tr>
<td>Asthma (prescribed bronchodilators or steroids)</td>
<td>146 (12)</td>
<td>210 (17)</td>
<td>.18</td>
</tr>
<tr>
<td>Seizure disorder (prescribed anticonvulsants)</td>
<td>112 (9)</td>
<td>112 (9)</td>
<td>.76</td>
</tr>
<tr>
<td>Neurologic/neuromuscular disorder putting patient at risk of aspiration</td>
<td>105 (9)</td>
<td>96 (8)</td>
<td>.62</td>
</tr>
<tr>
<td>Cancer (current or previous diagnosis)</td>
<td>88 (7)</td>
<td>109 (9)</td>
<td>.31</td>
</tr>
<tr>
<td>Known chromosomal abnormality</td>
<td>60 (5)</td>
<td>48 (4)</td>
<td>.24</td>
</tr>
<tr>
<td>Admitted with tracheostomy, No. (%)</td>
<td>11 (&lt;1)</td>
<td>11 (&lt;1)</td>
<td>.74</td>
</tr>
<tr>
<td>Intubated at other hospital and transferred to participating PICU, No. (%)</td>
<td>334 (27)</td>
<td>306 (25)</td>
<td>.23</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; OI, oxygenation index; OSI, oxygen saturation index; PARDS, pediatric acute respiratory distress syndrome<sup>11,12</sup>; POPC, Pediatric Cerebral Performance Category; PICU, pediatric intensive care unit; POPC, Pediatric Overall Performance Category; PRISM III-12, Pediatric Risk of Mortality III score from first 12 hours in the PICU.

*P values for comparison between groups were calculated using linear, cumulative logit, logistic, and multinomial logistic regression accounting for PICU as a cluster variable using generalized estimating equations for log-transformed continuous, ordinal, binary, and nominal variables, respectively.

<sup>b</sup>PCPC and POPC scores range from 1 to 6, with higher categories indicating greater impairment.

<sup>c</sup>Able to verbally communicate pain at baseline includes only patients aged 16 months or older.

<sup>d</sup>Other primary diagnoses include pulmonary edema, thoracic trauma, pulmonary hemorrhage, laryngotracheobronchitis, acute respiratory failure after bone marrow transplantation, acute chest syndrome/sickle cell disease, pertussis, pneumothorax (nontrauma), acute exacerbation lung disease (cystic fibrosis or bronchopulmonary dysplasia), acute respiratory failure related to multiple blood transfusions, pulmonary hypertension (not primary), and other.

<sup>e</sup>Oxygenation index was calculated as ([FiO2 × mean airway pressure]/PaO2 × 100). When an arterial blood gas measurement was not available, SpO2 was used to estimate PaO2 in order to calculate OSI ([FiO2 × mean airway pressure]/SpO2 × 100). Lower scores reflect better oxygenation.

**tween groups (intervention, 11%; control, 13%; *P* = .09). Consent rates were lower in the intervention PICUs (72% vs 84%; *P* = .01). Time from intubation to enrollment was shorter in the intervention PICUs (intervention: median, 21 hours [interquartile range 12-31 hours] vs control: median, 24 hours [IQR, 16-39 hours]; *P* = .002). Twenty-five patients were withdrawn from the intervention group: 10 parents withdrew full consent for the protocol and data collection, 8 parents withdrew consent for the protocol but allowed continued data collection, and 7 attending physicians opted to manage patients off protocol. Data from the 15 withdrawn patients with parental consent for data collection are included in the analysis.

Baseline patient characteristics were not statistically significantly different between the 2 groups except that the intervention group enrolled more patients younger than 2 years and more patients with bronchiolitis. In the youngest age group, intervention patients had a lower predicted risk of mortality compared with control patients (intervention: median risk of mortality, 1.7% [IQR, 0.7%-4.9%] vs control: median risk of mortality, 3.8% [IQR, 1.3%-9.5%]; *P* = .003) (Table 1). The
most prevalent diagnoses in both groups included pneumonia, bronchiolitis, and acute respiratory failure due to sepsis. Levels of oxygenation on day 1, early neuromuscular blockade use, and medical history were not statistically significantly different between groups.

Protocol Fidelity
At enrollment, 1155 intervention patients (94%) were receiving a combined sedation strategy of opioids and benzodiazepines, while an additional 43 patients (4%) were transitioned to this strategy within a median of 1 day (IQR, 1-3 days). Adherence to pain assessments did not differ by group, but sedation and withdrawal assessments were completed more frequently in the intervention group (for intervention vs control, respectively: pain, 89% vs 84% [P = .80]; sedation, 85% vs 69% [P = .01]; withdrawal, 65% vs 56% [P = .03]) (Table 5 in Supplement 1). Adherence to elements of the sedation protocol ranged from 71% to 100% of eligible study days and from 86% to 98% of patients (eTable 6 in Supplement 1). The daily SBS target was prescribed on 98% of intubated study days and achieved 95% of the time. Arousal assessments were recommended in 4% of titration and weaning phase days. When arousal assessments were performed, 61 patients achieved an awake state within a median of 300 minutes (IQR, 120-480 minutes) and 13 patients did not achieve an awake state, requiring sedative infusions to be discontinued or maintained at 50%. An ERT was recommended on 39% of intubated study days, and 80% of successful extubations occurred after achieving passing results on an ERT.

Outcomes
Primary Outcome
The duration of mechanical ventilation was not statistically significantly different between the 2 groups (intervention: median, 6.5 days [IQR, 4.1-11.2 days] vs control: median, 6.5 days [IQR, 3.7-12.1 days]; P = .61) (Table 2 and Figure 2). Adjusting for age group, PRISM III-12 score, and POPC score greater than 1 at enrollment, the HR for removal of mechanical ventilation comparing intervention vs control was 1.01 (95% CI, 0.85-1.19; P = .95). In this adjusted model, longer mechanical ventilation was associated with higher PRISM III-12 scores (HR, 0.98; 95% CI, 0.97-0.99 for a 1-point increase in PRISM III-12 score [P < .001]) and higher POPC category (HR, 0.74; 95% CI, 0.65-0.85 for POPC score >1 vs POPC score = 1 [P < .001]) but not with age group (HR, 1.08; 95% CI, 0.94-1.23 for the middle vs the youngest age group [P = .29] and HR, 1.10; 95% CI, 0.97-1.24 for the oldest vs the youngest age group [P = .13]).

Exploratory Secondary Outcomes
There were no group differences in the time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, or duration of assisted breathing including use of noninvasive ventilation after endotracheal extubation (Table 2). Fewer patients in the intervention group received neurological testing to evaluate a change in mental status (14% vs 19% in the control group; odds ratio [OR], 0.72; 95% CI, 0.53-0.97; P = .03) (Table 2 and eTable 7 in Supplement 1). There were no group differences in PICU and hospital lengths of stay or 28- or 90-day in-hospital mortality (Table 2 and eTable 8 in Supplement 1).

There were no significant differences in sedation-related adverse events including inadequate pain management, inadequate sedation management, clinically significant iatrogenic withdrawal, extubation failure, unplanned endotracheal tube/invasive line removal, ventilator-associated pneumonia, catheter-associated bloodstream infection, or new tracheostomy (Table 2). Two of 11 sedation-related adverse events were statistically significantly different between the groups (Table 7 in Supplement 1). First, more patients in the intervention group had postextubation stridor with chest wall retractions at rest (7% vs 4% in the control group; OR, 1.57; 95% CI, 1.04-2.37; P = .03). Although more intervention patients experienced stridor, there were no group differences in reintubation of these patients. Second, fewer intervention patients developed stage 2 or worse immobility-related pressure ulcers (<1% vs 2% in the control group; OR, 0.21; 95% CI, 0.08-0.53; P = .001).

Table 3 summarizes the sedation profiles of the 2 groups. The primary sedation strategy in the intervention group reflected the protocol; that is, the combined use of an opioid and benzodiazepine with morphine and midazolam as the primary agents. The primary sedation strategy in the control group predominantly included 3 agents: fentanyl as the primary opioid agent; midazolam and, to a lesser extent, lorazepam as the primary benzodiazepine agent; and dexmedetomidine. In addition, fewer patients in the intervention group received chloral hydrate (3% vs 15% in the control group; OR, 0.27; 95% CI, 0.10-0.75; P = .01). There were no differences in the mean daily, peak daily, and cumulative opioid and benzodiazepine doses between the 2 groups. Intervention patients had fewer days of exposure to opioids (median, 9 days vs 10 days in the control group; HR for days with no exposure, 1.27; 95% CI, 1.05-1.54; P = .01).

Measures of wakefulness, pain, and agitation varied by group (Table 3). The percentage of study days in which patients were awake and calm while intubated was higher in the intervention group (intervention: median, 86% [IQR, 67%-100%] vs control: median, 75% [IQR, 50%-100%]; P = .004) (Table 3). Patients in the intervention group had a greater percentage of days with any report of a pain score of 4 or higher (intervention: median, 50% [IQR, 27%-67%] vs control: median, 23% [IQR, 0%-46%]; P < .001) and any report of agitation with an SBS score of +1/+2 (intervention: median, 60% [IQR, 33%-80%] vs control: median, 40% [IQR, 13%-67%]; P = .003). There were no group differences in the percentage of study days with a modal pain score of less than 4 (no pain). Episodic reports of pain or agitation were higher in the intervention group but were effectively managed within 2 hours.

There were no differences in the occurrence of iatrogenic withdrawal by group (Table 3). Reflecting the protocol, fewer intervention patients received methadone (12% vs 30% in the control group; OR, 0.25; 95% CI, 0.14-0.45; P < .001). Across both groups, patients receiving methadone had longer opioid exposure and PICU and hospital lengths of stay (opioid exposure: median, 21 days [IQR, 14-29 days] vs 7 days [IQR, 4-13...
Post hoc analyses were conducted to test for group differences related to the cluster design and secular changes in sedation management over the enrollment period. We explored group differences stratified by age and diagnosis of days; \( P < .001 \); PICU length of stay: median, 15.3 days [IQR, 10.8-23.0 days] vs 8.4 days [IQR, 5.3-13.6 days]; \( P < .001 \); and hospital length of stay: median, 24 days [IQR, 16-38 days] vs 13 days [IQR, 8-22 days]; \( P < .001 \).

### Table 2. Study Outcomes According to Group*

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Sedation Protocol (n = 1225)</th>
<th>Usual Care (n = 1224)</th>
<th>( P ) Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of mechanical ventilation, median (IQR), d</td>
<td>6.5 (4.1-11.2)</td>
<td>6.5 (3.7-12.1)</td>
<td>.61</td>
</tr>
<tr>
<td>Adjusted for age group, PRISM III-12 score, and POPC score &gt;1 at enrollment(^c)</td>
<td></td>
<td></td>
<td>.95</td>
</tr>
<tr>
<td>Not successfully extubated by day 28, No. (%)</td>
<td>103 (8)</td>
<td>135 (11)</td>
<td>.19</td>
</tr>
<tr>
<td>Still intubated on day 28</td>
<td>40 (3)</td>
<td>62 (5)</td>
<td></td>
</tr>
<tr>
<td>Not extubated and died by day 28</td>
<td>41 (3)</td>
<td>54 (4)</td>
<td></td>
</tr>
<tr>
<td>Still intubated on transfer to another PICU by day 28</td>
<td>22 (2)</td>
<td>19 (2)</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary outcomes (nonsedation)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to recovery from acute respiratory failure, median (IQR), d(^d)</td>
<td>2.9 (1.3-6.0)</td>
<td>2.4 (1.1-5.7)</td>
<td>.91</td>
</tr>
<tr>
<td>Duration of weaning from mechanical ventilation, median (IQR), d(^d)</td>
<td>2.3 (1.1-4.3)</td>
<td>2.4 (1.2-5.1)</td>
<td>.33</td>
</tr>
<tr>
<td>Duration of assisted breathing, median (IQR), d(^d)</td>
<td>8.0 (4.8-14.1)</td>
<td>7.7 (4.1-14.8)</td>
<td>.97</td>
</tr>
<tr>
<td>Neurological testing, No. (%)</td>
<td>175 (14)</td>
<td>230 (19)</td>
<td>.03</td>
</tr>
<tr>
<td>Length of stay, median (IQR), d(^g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICU</td>
<td>9.6 (6.2-15.6)</td>
<td>9.6 (5.7-16.6)</td>
<td>.61</td>
</tr>
<tr>
<td>Hospital</td>
<td>14 (9-24)</td>
<td>16 (9-29)</td>
<td>.20</td>
</tr>
<tr>
<td>In-hospital mortality, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 28 d</td>
<td>47 (4)</td>
<td>63 (5)</td>
<td>.22</td>
</tr>
<tr>
<td>At 90 d</td>
<td>67 (5)</td>
<td>88 (7)</td>
<td>.18</td>
</tr>
<tr>
<td>Sedation-related adverse events(^{2,22})</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inadequate pain management, No. (%)(^h)</td>
<td>195 (16)</td>
<td>174 (14)</td>
<td>.65</td>
</tr>
<tr>
<td>Inadequate sedation management, No. (%)(^i)</td>
<td>301 (25)</td>
<td>246 (20)</td>
<td>.93</td>
</tr>
<tr>
<td>Clinically significant iatrogenic withdrawal, No. (%)(^i)</td>
<td>149 (12)</td>
<td>114 (9)</td>
<td>.80</td>
</tr>
<tr>
<td>Extubation failure (reintubation within 24 h), No. (%)</td>
<td>97 (8)</td>
<td>104 (9)</td>
<td>.56</td>
</tr>
<tr>
<td>Postextubation stridor with chest-wall retractions at rest, No. (%)</td>
<td>88 (7)</td>
<td>55 (4)</td>
<td>.03</td>
</tr>
<tr>
<td>Unplanned endotracheal tube extubation, No. of events/100 ventilator days</td>
<td>0.41</td>
<td>0.53</td>
<td>.76</td>
</tr>
<tr>
<td>Unplanned removal of any invasive tube, No. of events/100 device days</td>
<td>0.16</td>
<td>0.12</td>
<td>.22</td>
</tr>
<tr>
<td>Ventilator-associated pneumonia, No. of events/1000 ventilator days</td>
<td>0.53</td>
<td>0.77</td>
<td>.38</td>
</tr>
<tr>
<td>Catheter-associated bloodstream infection, No. of events/1000 central line days</td>
<td>0.86</td>
<td>0.77</td>
<td>.64</td>
</tr>
<tr>
<td>Immobility-related stage ≥2 pressure ulcers, No. (%)</td>
<td>5 (&lt;1)</td>
<td>19 (2)</td>
<td>.001</td>
</tr>
<tr>
<td>New tracheostomy, No. (%)(^k)</td>
<td>16 (1)</td>
<td>33 (3)</td>
<td>.12</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; PICU, pediatric intensive care unit; POPC, Pediatric Overall Performance Category; PRISM III-12, Pediatric Risk of Mortality III score from first 12 hours in the PICU.

\(^a\) See eTable 4 in Supplement 1 for outcomes definitions.

\(^b\) \( P \) values for comparison between groups were calculated using proportional hazards, logistic, and Poisson regression accounting for PICU as a cluster variable using generalized estimating equations for time-to-event, binary, and rate variables, respectively, except where otherwise noted under primary outcome.

\(^c\) After adjusting for age group, PRISM III-12 score, and POPC score >1 at enrollment, the intraclass correlation coefficient based on the deviance residuals was 0.046.

\(^d\) Time to recovery from acute respiratory failure excludes 120 nonsurvivors who did not meet criteria prior to death. For the 213 survivors who never met criteria, the duration of recovery was set as equal to the duration of mechanical ventilation if the patient was successfully extubated or to 28 days if the patient was still intubated on day 28 or transferred to another ICU while still intubated.

\(^e\) Duration of assisted breathing continued until the first time pressure support was <5 cm H\(_2\)O (continuous or bilevel) for at least 24 hours. Patients were assigned 28 days if they continued to receive pressure support ≥5 cm H\(_2\)O or were transferred or died prior to day 28 without remaining off of pressure support ≥5 cm H\(_2\)O for >24 hours.

\(^f\) PICU and hospital length of stay exclude all nonsurvivors. Patients still in the PICU or hospital on day 90 were censored at day 90.

\(^g\) Inadequate pain management was defined as a pain score >4 (or pain assumed present if receiving neuromuscular blockade) for 2 consecutive hours not related to a planned extubation attempt.

\(^h\) Clinically significant iatrogenic withdrawal was defined as rescue therapy (an opioid or benzodiazepine bolus or an increase in opioid or benzodiazepine infusion) to manage an increase in withdrawal symptoms for patients weaning from ≥5 days of opioids.

\(^i\) Excludes 22 patients admitted with tracheostomies.
bronchodilators and found no differences in duration of mechanical ventilation or sedative exposure (eTables 10 and 11 in Supplement 1). In both groups, the primary sedation strategy remained the combined use of an opioid and benzodiazepine. The usual care group did not adopt protocolized sedation during the trial. Supplemental use of dexmedetomidine increased each year in both groups and was used more often in the control group (eTable 12 in Supplement 1).

Discussion

This multicenter cluster randomized study of 2449 pediatric patients with acute respiratory failure showed no difference in the duration of mechanical ventilation for patients managed per sedation protocol compared with patients receiving usual care. Exploratory analyses of several secondary outcomes indicated that the sedation protocol was associated with a difference in patients' sedation experience; patients in the intervention group were more awake and calm while intubated, receiving fewer days of opioid exposure and fewer sedative classes without an increase in inadequate pain or sedation management or clinically significant iatrogenic withdrawal compared with patients receiving usual care, but they had more days with any report of pain and agitation, suggesting a complex relationship among wakefulness, pain, and agitation.

Targeting a sedation goal of patients who are calm, easily aroused, and readily evaluated is attainable and safe in children undergoing ventilation for acute respiratory failure. Prescribing a more awake state during the titration phase of illness decreased sedation exposure and allowed an accelerated weaning schedule from the patient's primary agent that commenced at a lower starting opioid dose. This strategy decreased the need for methadone conversion. The net result was shorter opioid exposure with comparable WAT-1 scores.

Adjustment of sedatives according to trajectory of illness diminished the need for arousal assessments. Few patients were unresponsive or responsive only to noxious stimuli in the titration or weaning phases of the protocol. Patients who are more awake and calm are better able to communicate their level of discomfort, interact meaningfully with their parents and caregivers, and participate in neurological assessments. Episodic pain and agitation were assessed more often in intervention patients and effectively managed in the context of fewer sedative classes and exposure days.

More intervention patients experienced postextubation stridor and fewer had clinically significant pressure ulcers. Patients who are more awake are better able to move, which may produce airway irritation but also allows patients to reposition themselves to avoid pressure-related skin injury. Pressure ulcers are a serious iatrogenic injury adding to the personal and financial burden of critical illness. Shifting treatment approaches away from inactivity may also be helpful given the evolving knowledge on the consequences of critical illness on neuromuscular function in adults. Although follow-up studies of more awake adult intensive care patients demonstrate no adverse outcomes, the relationships among PICU awareness, amnesia, and neurobehavioral outcomes in children are unknown and the subject of future inquiry in a subset of patients.

Intensive care is practiced within an interprofessional team sharing responsibility for patient outcomes. The study protocol focused on how physicians, nurses, pharmacists, and respiratory therapists collaborate to set sedation goals for an individual patient and how sedatives are adjusted to meet a patient's evolving state and readiness for extubation. Unique features of the protocol include disrupting the status quo by using different sedation targets per phase of illness, mandating a decision about sedation adjustment every 8 hours, providing recommendations on when to use secondary agents, and providing a systematic plan to wean high-risk patients. Our data show that the protocol can be implemented to reduce variation in sedation management and that PICU nurses, working within an interprofessional team, can safely manage sedation in more awake and calm pediatric patients.

Our study has limitations, some of which reflect a cluster randomized design. The intervention group enrolled more patients younger than 2 years and more patients with bronchiolitis—patients who are often difficult to sedate. Selection bias may have occurred because the trial was unblinded. We minimized this potential bias by using explicit enrollment criteria, monitoring sedation practices in both groups, following well-defined outcomes including prespecified adverse events, and using a statistical analysis plan designed a priori that adjusted for age group, PRISM III-12 score, and functional health at enrollment and accounted for PICU as a cluster variable. Post hoc analyses were conducted to test for group differences related to baseline imbalances, and we found no differences in duration of mechanical ventilation or sedative exposure. Including 31 sites allowed potential bias to be distributed across multiple PICUs with varied baseline practices. This approach allowed a comprehensive assessment of risk that increases the generalizability of study results to a large...
Table 3. Sedation Profiles According to Groupa

<table>
<thead>
<tr>
<th>Variables</th>
<th>Sedation Protocol (n = 1225)</th>
<th>Usual Care (n = 1224)</th>
<th>P Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sedatives administered</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary opioid agent, No. (%)c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>782 (64)</td>
<td>210 (17)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>431 (35)</td>
<td>989 (81)</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone (nonprotocol sedative)</td>
<td>2 (&lt;1)</td>
<td>10 (&lt;1)</td>
<td></td>
</tr>
<tr>
<td>Remifentanil (nonprotocol sedative)</td>
<td>1 (&lt;1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>9 (&lt;1)</td>
<td>15 (1)</td>
<td></td>
</tr>
<tr>
<td>Opioid exposure, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean daily dose, mg/kg</td>
<td>1.3 (0.7-2.6)</td>
<td>1.7 (0.8-2.9)</td>
<td>.13</td>
</tr>
<tr>
<td>Peak daily dose, mg/kg</td>
<td>3.3 (1.6-6.1)</td>
<td>4.0 (2.0-7.0)</td>
<td>.16</td>
</tr>
<tr>
<td>Cumulative dose, mg/kg</td>
<td>13.7 (5.3-38.3)</td>
<td>17.7 (5.3-32.9)</td>
<td>.10</td>
</tr>
<tr>
<td>No. of exposure days</td>
<td>9 (5-15)</td>
<td>10 (4-21)</td>
<td>.01</td>
</tr>
<tr>
<td>Primary benzodiazepine agent, No. (%)c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>1087 (89)</td>
<td>1009 (82)</td>
<td>.02</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>128 (10)</td>
<td>206 (17)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>10 (&lt;1)</td>
<td>9 (&lt;1)</td>
<td></td>
</tr>
<tr>
<td>Benzodiazepine exposure, median (IQR), mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean daily dose</td>
<td>1.3 (0.6-2.7)</td>
<td>1.3 (0.6-2.5)</td>
<td>.22</td>
</tr>
<tr>
<td>Peak daily dose</td>
<td>2.9 (1.5-6.0)</td>
<td>3.2 (1.5-6.7)</td>
<td>.77</td>
</tr>
<tr>
<td>Cumulative dose</td>
<td>14.0 (5.1-41.5)</td>
<td>13.6 (4.3-42.4)</td>
<td>.54</td>
</tr>
<tr>
<td>Secondary sedatives, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexmedetomidine</td>
<td>287 (23)</td>
<td>596 (49)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Propofol</td>
<td>171 (14)</td>
<td>137 (11)</td>
<td>.87</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>142 (12)</td>
<td>226 (18)</td>
<td>.37</td>
</tr>
<tr>
<td>Ketamine</td>
<td>261 (21)</td>
<td>368 (30)</td>
<td>.06</td>
</tr>
<tr>
<td>Clonidine</td>
<td>149 (12)</td>
<td>163 (13)</td>
<td>.87</td>
</tr>
<tr>
<td>Methadone</td>
<td>148 (12)</td>
<td>368 (30)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Chloral hydrate (nonprotocol sedative)</td>
<td>34 (3)</td>
<td>181 (15)</td>
<td>.01</td>
</tr>
<tr>
<td>No. of different sedative classes received, No. (%)d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1 (&lt;1)</td>
<td>2 (&lt;1)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>9 (&lt;1)</td>
<td>10 (&lt;1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>620 (51)</td>
<td>350 (29)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>347 (28)</td>
<td>416 (34)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>167 (14)</td>
<td>264 (22)</td>
<td></td>
</tr>
<tr>
<td>5-7</td>
<td>81 (7)</td>
<td>182 (15)</td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>2 (2-3)</td>
<td>3 (2-4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypnotic medications, No. (%)</td>
<td>82 (7)</td>
<td>81 (7)</td>
<td>.57</td>
</tr>
<tr>
<td>Antidelerium medications, No. (%)</td>
<td>20 (2)</td>
<td>26 (2)</td>
<td>.33</td>
</tr>
<tr>
<td>Neuromuscular blockade to manage agitation, No. (%)</td>
<td>290 (24)</td>
<td>326 (27)</td>
<td>.66</td>
</tr>
<tr>
<td>Measures of wakefulness, pain, and agitation, median (IQR)</td>
<td>86 (67-100)</td>
<td>75 (50-100)</td>
<td>.004</td>
</tr>
<tr>
<td>Days to first awake/calm stateae</td>
<td>2 (1-4)</td>
<td>2 (1-4)</td>
<td>.09</td>
</tr>
<tr>
<td>Study days with modal pain score &lt;4, %</td>
<td>100 (100-100)</td>
<td>100 (100-100)</td>
<td>.84</td>
</tr>
<tr>
<td>Study days with an episode of pain (highest pain score ≥4), %</td>
<td>50 (27-67)</td>
<td>23 (0-46)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Study days with an episode of agitation (highest SBS score +1 or +2), %</td>
<td>60 (33-80)</td>
<td>40 (13-67)</td>
<td>.003</td>
</tr>
<tr>
<td>Occurrence of iatrogenic withdrawalae</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iatrogenic withdrawal syndrome (WAT-1 score ever ≥3), No. (%)</td>
<td>450 (68)</td>
<td>336 (68)</td>
<td>.80</td>
</tr>
<tr>
<td>Peak WAT-1 score, median (IQR)</td>
<td>4 (2-5)</td>
<td>4 (2-6)</td>
<td>.90</td>
</tr>
<tr>
<td>Study days with WAT-1 score ≥3, median (IQR), %</td>
<td>25 (0-50)</td>
<td>25 (0-50)</td>
<td>.83</td>
</tr>
</tbody>
</table>

Abbreviations. IQR, interquartile range; SBS, State Behavioral Scale; WAT-1, Withdrawal Assessment Tool–Version 1.

a See Table 4 in Supplement 1 for outcomes definitions.
b P values for comparison between groups were calculated using logistic, linear, and proportional hazards regression accounting for PICU as a cluster variable using generalized estimating equations for binary variables, log-transformed continuous variables (except percentage of study days variables), and time-to-event variables, respectively.
c Primary opioid agent was defined as the opioid administered via continuous infusion. If no opioid or more than 1 opioid was administered via continuous infusion, primary opioid agent was defined as the opioid administered on the highest percentage of study days. If morphine and fentanyl were administered on the same number of days, primary opioid agent was assigned as the opioid contributing the highest morphine equivalents.
d Primary benzodiazepine agent was defined similarly. If midazolam and lorazepam were administered on the same number of days, primary benzodiazepine agent was assigned as the benzodiazepine contributing the highest midazolam equivalents.
eThis P value compares primary agent morphine vs fentanyl between groups. Fentanyl was recommended in patients with profound hypotension, unremitting reactive airways disease, or intolerance to morphine.
f This P value compares primary agent midazolam vs lorazepam between groups. Enteral lorazepam was recommended if intravenous access was a problem or if the patient was tolerating enteral feedings.
g Different sedative classes include opioids, benzodiazepines, α2-adrenergic agonists, propofol, barbiturates, ketamine, and chloral hydrate.
h See the eFigure in Supplement 1.
iWAT-1 scores range from 0 to 12; higher WAT-1 scores indicate more withdrawal symptoms; WAT-1 scores ≥3 are associated with clinically significant withdrawal symptoms. Occurrence of iatrogenic withdrawal was calculated for 1157 survivors who completed weaning from ≥5 days of opioids and had at least 1 WAT-1 assessment (n=660 intervention and n=497 control patients).
Sedation practices could be optimized if the pharmacokinetic and pharmacodynamic profiles of sedatives in critically ill pediatric patients were better described. Although RESTORE focused on the process of how sedatives are administered, future studies should compare the best sedative agent for varied lengths of critical illness. Outcomes of interest include efficacy as well as an evaluation of the immediate risk-benefit ratio and an evaluation of the long-term effect of sedatives on neurocognitive development and posttraumatic stress.

Conclusions
Among children undergoing mechanical ventilation for acute respiratory failure, the use of a nurse-implemented, goal-directed sedation protocol compared with usual care did not reduce the duration of mechanical ventilation. Exploratory analyses of the secondary outcomes suggest a complex relationship among wakefulness, pain, and agitation.

ARTICLE INFORMATION

Author Affiliations: School of Nursing and Perelman School of Medicine, University of Pennsylvania, Philadelphia (Curley); Critical Care and Cardiovascular Program, Boston Children's Hospital, Boston, Massachusetts (Curley); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (Wy pij); Department of Pediatrics, Harvard Medical School, Boston, Massachusetts (Wypij); Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts (Wy pij, Asaro); Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, Washington (Watson); Clinical Research, Investigation, and Systems Modeling of Acute Illness Center, Pittsburgh, Pennsylvania (Wy pij, Angus); Pediatric Critical Care, Primary Children's Hospital, Salt Lake City, Utah (Grant); Duke University Medical Center, Durham, North Carolina (Cheifetz); Department of Pharmacy, Boston Children's Hospital, Boston, Massachusetts (Dodson); University of California at San Francisco School of Nursing, San Francisco (Fr ank); Department of Pediatrics, Medical College of Wisconsin, Milwaukee (Gedelt); University of California at San Francisco School of Medicine, San Francisco (Matthay).

Author Contributions: Drs Curley and Wypij had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Curley, Wypij, Watson, Dodson, Franck, Gedelt, Angus, Matthay. Acquisition, analysis, or interpretation of data: Curley, Wypij, Watson, Grant, Asaro, Cheifetz, Franck, Angus, Matthay. Drafting of the manuscript: Curley, Wypij, Watson, Asaro, Franck, Matthay. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Wypij, Asaro. Obtained funding: Curley, Wypij. Administrative, technical, or material support: Curley, Grant, Gedelt, Franck, Gedelt, Angus, Matthay. Study supervision: Curley, Wypij, Watson, Asaro.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Cheifetz reports personal fees for serving as a medical advisor for Philips. Dr Matthay reports personal fees for serving as chair of a data and safety monitoring board for Roche-Genentech and as a consultant for Cersus, Quark Pharmaceuticals, Biogen, and GlaxoSmithKline. No other disclosures were reported.

Funding/Support: This study was supported by grants from the National Heart, Lung, and Blood Institute and the National Institute of Nursing Research, National Institutes of Health (grant U01 HL086622 to Dr Curley and grant U01 HL086649 to Dr Wypij).

Role of the Funder/Sponsor: The study funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Disclaimer: Dr Angus, JAMA Associate Editor, was not involved in the review of or decision to publish this article.

Additional Contributions are listed in Supplement 1.

REFERENCES


